Cell & Gene Therapies (CGTs) market continues to grow at a tearing 29% CAGR as more investments come in, regulators approve more therapies, and medical fraternity's confidence in the new therapies increase. The industry is responding with innovations such as closed loop systems, automation, and collaboration enablement. Drug sponsors are now looking for ways to scale-up their operations, and one way to do so is leveraging CDMOs. The partnership with CDMOs is emerging more as an imperative than as an option. Two recent articles, one written by Amit Agarwal & Omkar Kawalekar, and another by OBiO Tech, outline the advantages and challenges in adopting this approach. While the Deloitte article presents an outside-in perspective, OBiO's article presents the case from the perspective of a CDMO. Advantages of leveraging CDMOs are outlined in these articles: cost optimization, accelerated time to market, reduced regulatory risk, availability of experienced resources, project flexibility & adaptability, and project management & execution capability. AI is penetrating the world of CGTs. Key examples being optimizing and streamlining supply and demand, sales & operations planning, and compiling EBRs and regulatory submission documents using intelligent document processing. Collaboration emerges as a common thread in these articles. OBiO says, "During the length of your partnership, it is critical to create an environment of collaboration and transparent communication which will help to foster trust and achieve mutually beneficial project goals." Amit & Omkar write: "The best companies (CDMOs) offer tracking and collaboration technologies that improve visibility for drug sponsors and help to build trust by ensuring transparency. To derive the most benefit from AI and other technologies, CDMOs and drug developers must work together and break down the barriers that separate them. They should share costs and data and collaborate on thought leadership." Collabrix Inc. specializes in enabling collaboration in the life sciences and healthcare industries, with our tagline being "Collaborate for life." Our SaaS products enable collaboration across stakeholders that work together to ultimately deliver the therapies to patients. Alpatia establishes a network of stakeholders such as drug sponsors, CDMOs, couriers, external testing labs, hospitals and doctors, and enables collaborative execution of cross-enterprise workflows across these entities for both, autologous and allogeneic therapies. Mosymphony covers the range of interactions between drug sponsor and CDMO. Starting with sharing the manufacturing schedule, so the CDMO can plan their operations. On the other hand, the CDMO shares availability of resources to meet the sponsors' plans. And so this interaction continues through manufacturing and quality processes. Reach out to us at [email protected] to know more. #CellTherapies #GeneTherapies #CDMOs #Collaboration #HealthcareInnovation
关于我们
At Collabrix, we enhance collaboration, streamline operations, and ensure compliance across the life sciences and healthcare value stream. Our vision is to enable stakeholders in these industries to seamlessly collaborate using digital technologies, ultimately improving patient experience and outcomes. We use AI and peer-to-peer enterprise blockchain technologies, thus making our SaaS solutions scalable, resilient, secure, and fully auditable.
- 网站
-
https://collabrix.co/home
Collabrix Inc.的外部链接
- 所属行业
- 信息服务
- 规模
- 11-50 人
- 总部
- San Jose,California
- 类型
- 私人持股
- 创立
- 2018
- 领域
- SaaS、for Ecosystems、powered by、Enterprise Blockchain、Smart Contracts、Pharmaceutical、Contract Manufacturing、Pharmaceutical Contract Manufacturing System、PCMP、multi-tenant platform、Secure pharmaceutical management和team management
地点
Collabrix Inc.员工
-
Raheel Retiwalla
Chief Strategy Officer @ Productive Edge | Healthcare Digital Strategy
-
Dr. Vishal Gandhi PhD,MBA
Founder & CEO @ BIORx Venture Advisors | Lead @ Indian Healthcare Angels | Startup Mentor | Angel Investor | Growth & Strategy Consultant | Venture…
-
Sasank Avantsa
Infrastructure Manager @ Schrocken Inc. | Cloud Infrastructure | AWS | Azure | Automation | Node.js
-
Tanya Priyadarshani
M.tech Biotechnology student
动态
-
I’m pleased to share that I’ll be attending the India Biopharma Leaders Conclave on June 13th and 14th in Hyderabad. This event gathers industry leaders to discuss key trends and opportunities in biopharma. I look forward to insightful discussions and networking with peers in the field. If you're attending, let’s connect! #Biopharma #IndiaBiopharmaLeadersConclave #Networking
-
Schrocken Inc. had set-up a stall recently at BioAsia 2024 in Hyderabad. Here are some thoughts that I shared during the event.
For five years, we've facilitated life sciences collaboration. Alpatia accelerates cell and gene therapy delivery, targeting contract manufacturing and therapy sectors. Bio Asia provided a vital platform, connecting us with global partners and customers. #Alpatia #CellTherapy #GeneTherapy #BioAsia #LifeSciences #Innovation #Collaboration Sanjay Kuberkar Schrocken Inc. BioAsia 2024 Major Sunil Shetty, SM(retd) My Startup TV My Startup Life! My Startup OTT Vamsi Prashanth Muthangi Paridhi Gupta Atal Incubation Centre - CCMB Viswanadham Duppatla IKP Knowledge Park SRiX -SR Innovation Exchange Col BS Rao NIPER Hyderabad Government of India Ministry of Health and Family Welfare, Government of India Government of Telangana Laurus Labs Limited Dr. Reddy's Laboratories